KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
← catalyst calendarSponsored by Kyverna Therapeutics (industry) · KYTX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
27actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-25 | actual | When the study began enrolling |
| Primary completion | 2026-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-25 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Stiff-Person Syndrome
- SPS
Intervention
- Biological: Standard lymphodepletion regimen — also filed as Cyclophosphamide, Fludarabine
Primary outcomes
what the primary-completion date above is the date OFTo evaluate efficacy of KYV-101
measured Up to 12 months
To evaluate the safety of KYV-101
measured Up to 12 months
Publications
- PMID 37059468 — cited as background
- PMID 19349711 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · KYTX's whole pipeline · Catalyst calendar · Every registered study · What changed